Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

AB1569

Sigma-Aldrich

Anti-Dopa Decarboxylase Antibody

Chemicon®, from rabbit

Sinonimo/i:

Anti-AADC

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Origine biologica

rabbit

Livello qualitativo

100

Forma dell’anticorpo

affinity purified immunoglobulin

Tipo di anticorpo

primary antibodies

Clone

polyclonal

Purificato mediante

affinity chromatography

Reattività contro le specie

canine, bovine, rat, guinea pig, human, sheep

Produttore/marchio commerciale

Chemicon®

tecniche

immunohistochemistry: suitable
western blot: suitable

N° accesso NCBI

NM_000790.3
NM_001082971.1

N° accesso UniProt

P20711

Condizioni di spedizione

dry ice

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

human ... CDNF(441549)

Specificità

DOPA Decarboxylase (DDC). Reacts with a single band of ~55 kDa by Western blot.

Immunogeno

Recombinant bovine DDC expressed in E. coli and purified from inclusion bodies.

Applicazioni

Detect Dopa Decarboxylase using this Anti-Dopa Decarboxylase Antibody validated for use in IH & WB.
Immunoblotting: 1:500-1:1,000

Immunohistochemistry using formaldehyde-fixed brain sections.

Optimal working dilutions must be determined by the end user.
Research Category
Neuroscience
Research Sub Category
Neurotransmitters & Receptors

Neuronal & Glial Markers

Stato fisico

Affinity purified immunoglobulin. Liquid in 10 mM HEPES, pH 7.5, 150 mM NaCl, 100 μg/mL BSA and 50% glycerol.

Stoccaggio e stabilità

Maintain at -20 to -80°C in undiluted aliquots for up to six months after date of receipt. Store in a NON-self-defrosting freezer. Avoid repeated freeze-thaw cycles.

Altre note

2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research

Note legali

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Lack of regulation of aromatic L-amino acid decarboxylase in intact bovine chromaffin cells.
Jack C Waymire, John W Haycock
Journal of Neurochemistry null
Branden J Stansley et al.
Neuropharmacology, 67, 243-251 (2012-12-01)
L-dopa is a precursor for dopamine synthesis and a mainstay treatment for Parkinson's disease. However, l-dopa therapy is not without side effects that may be attributed to non-dopaminergic mechanisms. Synthesized dopamine can be neurotoxic through its enzymatic degradation by monoamine
Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal.
Anne-Marie Duchemin,Hailing Zhang,Norton H Neff,Maria Hadjiconstantinou
Neuroscience Letters null
Innate immunity in insects: surface-associated dopa decarboxylase-dependent pathways regulate phagocytosis, nodulation and melanization in medfly haemocytes.
Sideri, M; Tsakas, S; Markoutsa, E; Lampropoulou, M; Marmaras, VJ
Immunology null
Jennifer M King et al.
Life sciences, 89(17-18), 638-643 (2011-08-30)
l-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective symptomatic treatment for Parkinson's disease (PD), but PD patients usually experience a successful response to L-DOPA therapy followed by a progressive loss of response. L-DOPA efficacy relies on its decarboxylation by aromatic l-amino acid
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.